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IODNE: An Integrated Optimization Method for
Identifying the Deregulated Subnetwork for
Precision Medicine in Cancer
S Mounika Inavolu1,2, J Renbarger3, M Radovich1,2, V Vasudevaraja1,2, GH Kinnebrew1,2, S Zhang1,2 and L Cheng1,2,3*
Subnetwork analysis can explore complex patterns of entire molecular pathways for the purpose of drug target identification. In
this article, the gene expression profiles of a cohort of patients with breast cancer are integrated with protein-protein interaction
(PPI) networks using, simultaneously, both edge scoring and node scoring. A novel optimization algorithm, integrated
optimization method to identify deregulated subnetwork (IODNE), is developed to search for the optimal dysregulated subnetwork
of the merged gene and protein network. IODNE is applied to select subnetworks for Luminal-A breast cancer from The Cancer
Genome Atlas (TCGA) data. A large fraction of cancer-related genes and the well-known clinical targets, ER1/PR and HER2, are
found by IODNE. This validates the utility of IODNE. When applying IODNE to the triple-negative breast cancer (TNBC) subtype
data, we identified subnetworks that contain genes such as ERBB2, HRAS, PGR, CAD, POLE, and SLC2A1.
CPT Pharmacometrics Syst. Pharmacol. (2017) 6, 168–176; doi:10.1002/psp4.12167; published online 7 March 2017.
Study Highlights
WHAT ISTHECURRENTKNOWLEDGEONTHETOPIC?
 The topic was to design an optimization-searching
algorithm, IODNE, which uses the intersection of
gene and protein networks to obtain a dysregulated
subnetwork for drug target selection in a cohort of
patients.
WHAT QUESTION DID THIS STUDY ADDRESS?
 How to combine networks information of gene-gene
and protein-protein? How to search an optimum
gene subnetwork for drug treatment for a cohort of
patients?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Networks’ combination between gene regulatory net-
works and PPI networks (PPIs). A gene subnetwork
searching of drug targets for breast cancer subtypes
Luminal-A and TNBC.
HOW THIS MIGHT CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS
 Integrating gene and protein network and pharmacol-
ogy, an optimizing subnetwork searching for drug tar-
gets selection holds the promise of expanding the
current opportunity space and a cohort of patient’s ther-
apeutics in the clinic systematically.
Systematic network analysis on cancer has multiple potential
biological and clinical applications. A better understanding of
the effects of gene/protein interaction may lead to the identifica-
tion of cancer genes and correlated pathways, which, in turn,
may offer better targets for drug development in cancer treat-
ment.1 Genomewide mRNA expression data provide a rich
resource for studying the molecular mechanisms of cancer.2
The reconstruction or “reverse engineering” of gene regulatory
networks, which aim to find the underlying network of gene–
gene interactions from the measurement of gene expression, is
considered one of most important goals in systems biology.3–5
Gene expression products are most often proteins. Large scale
statistical analysis shows that the single gene signal transduc-
tion from gene expression to protein amount is not synchro-
nous, but random.6 The protein-protein interaction (PPI)
network provides a fundamental basis for understanding the
role of proteins within the cell by examining their physical and/or
functional associations. Pathway Commons7 is a comprehen-
sive public pathway database (http://www.pathwaycommons.
org/), integrating Human IntAct,8 BioGrid,9 human protein
reference database,10 Kyoto Encyclopedia of Genes and
Genomes,11 and 10 more famous PPI datasets. A large amount
of gene network research is based on either gene or protein
data.12 However, according to literature,13 the protein pairs
encoded by coexpressed genes interact with each other more
frequently than random proteins. This suggests that if gene-
gene and PPIs are taken into account simultaneously in one
computational method, it will increase the accuracy of identifica-
tion of interactions of both types as well as allow the recognition
of overlapping patterns between gene and protein networks. In
this article, the gene expression profile of a cohort of patients
with cancer is used to generate coexpression networks, which
are then integrated with PPI networks for observing gene varia-
tion systematically.
Gene/protein interaction networks can guide us in under-
standing the gene module molecular mechanisms in a system
biology level.14 However, an exhaustive dataset that holds
all of the interactions between genes or proteins in major
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biological pathways in cancer is difficult to find. Searching for
condition-specific subnetworks can help us identify the most
significant subsets of the holistic cancer genome. In general,
subnetwork search algorithms can be broadly classified into
two types15–18: (1) seed-initiated algorithms; and (2) scoring
search algorithms.19 Seed-based algorithms involve a set of
predefined significant genes that aid in the detection of the
subnetworks, such as SubNet,20 which uses a version of Goo-
gle’s PageRank algorithm for seed detection. Scoring search
algorithms work by treating all genes as having equal signifi-
cance initially, deploy a scoring function to rank the genes, and
finally use a search algorithm to extract the subnetworks. The
typical scoring strategies include edge-based scoring, node-
based scoring, and combined edge and node-based scoring.
Guo et al.21 introduce an edge-based scoring and search
approach for extraction of a PPI subnetwork responsive to con-
ditions related to some investigated gene expression profiles.
However, the node (gene) function is ignored in the algorithm.
Node-based scoring has also been used to identify disease-
specific genes. Dezso et al.22 score each node by the number
of paths traversing that node in the disease-specific network in
relation to the number of paths going via the same node in the
global network. However, edge weights are not taken into
account. Amgalan & Lee23 proposed the weighted maximum
clique method to identify a condition-specific subnetwork by
both edge-based scoring and node-based scoring. However,
drug targets are not discussed. So far, there is still a lack of a
tool for extracting subnetworks from integrated gene-gene and
PPI networks for the most significant dysregulated network in
cancer, especially with regard to drug treatment in a specific
condition. We propose a novel integrated optimization method
for identifying the dysregulated subnetwork (IODNE) for a can-
cer cohort. Edge and node scoring jointly measure condition-
specific changes to both gene-gene coexpressions and PPIs.
Unfortunately, the derivation of a computational model that
extracts the optimum subnetwork is a nondeterministic polyno-
mial time-hard problem24 and biomolecular networks are mas-
sive in scale. This huge dimension makes it tedious to extract
globally optimum subnetworks. The Kruskal tree algorithm is a
fast searching strategy to find the most connecting significant
genes by the shortest spanning subtree of a gene connection
network.25
Breast cancer is one of the most common cancer types
and is the second leading cause of cancer deaths in wom-
en.26 Nearly 40% of patients with breast cancer lack specific
gene biomarker identification and have to receive chemother-
apy over-treatment and suffer from its strong side effects in
the clinic.27,28 The estrogen receptor (ER) or progesterone
receptor (PR) positive tumors (i.e., Luminal-A) usually receive
endocrine (hormone) therapy as the standard treatment.29
The HER2 amplified tumor responds well to HER2 targeted
trastuzumab, which is currently the standard. However, triple-
negative breast cancer (TNBC; ER2/PR2, HER22) is the
most aggressive tumor type and has a much shorter overall
survival than the other tumor types. Currently, chemotherapy
is still the main therapy for TNBC.30 The Cancer Genome
Atlas (TCGA)31 provides comprehensive cancer genome pro-
files for more than 14,000 cancers, including gene expression
profiles. This rich source of data provides us an opportunity
to detect the molecular variation in subtype-specific breast
cancer.
In this article, an integrated optimization method (IODNE)
is proposed for the identification of the maximum dysregu-
lated subnetwork for drug treatment in a subtype of patients.
We use a strategy of subnetwork retrieval, which depends on
the gene-gene control network merged with PPIs and rank
subnetworks by scoring both edges and nodes. Comparison
of transcriptomes between a subtype of patients with breast
cancer and a corresponding normal group is used to con-
struct the gene-gene control network. A modified Kruskal
minimum spanning tree search strategy determines the maxi-
mum dysregulated subnetwork for drug treatment in a cohort
of patients. The novel algorithm is validated by its ability to
select previously known drug target genes in Luminal-A
breast cancer from TCGA. IODNE is applied to TNBC for
drug-target subnetwork identification.
METHODS
Materials
We attempted to find the major differences in network pat-
terns between two groups from their specific gene regulatory
networks and a prior knowledge of a protein-protein network.
The gene expression profiles pertaining to Luminal-A and
TNBC were collected from TCGA,27 including tumor samples
and their adjacent normal tissue. The expression data was
derived from the Agilent-G450-2A Array-based platform,
which consisted of 17,815 genes. There are nine pairs of
TNBC samples with their respective adjacent-normal sam-
ples. The Luminal-A expression set consisted of 43 pairs of
tumors and corresponding adjacent-normal samples.
Supplementary File S1 provides clinical information and
subtypes of breast cancer. Pathway Commons 2 (version
7)10 (http://www.pathwaycommons.org) is a well-known col-
lection of biological pathways and PPI network knowledge.
Pathway Commons consists of 31,698 pathways, 1,912,848
edges (PPI), and 14,863 nodes (genes), which were used
for this analysis. Drug-targeted genes were annotated by
DrugBank database version 4.032 (http://www.drugbank.ca/
drugs). We collected 1,623 US Food and Drug Administration
(FDA) approved drugs and their 1,770 targets (Supplementary
File S8). According to the National Cancer Institute and the
National Comprehensive Cancer Network annotation,33 134
FDA approved cancer drugs and 322 target genes are “signed,”
which are annotated as either enhancing or repressing the
target (Supplementary File S9).
The preprocessing pipeline of IODNE is well structured
to organize the bulk gene expression data into the desired
input format suited for the main run, as shown in Table 1.
The rows show each gene’s expression and the columns
show different samples. The first row shows the information
of the group samples, such as tumor or adjacent normal
group; and the second row shows the subtypes of tumors.
IODNE is capable of recognizing the various subtypes
of cancers and the type of tissue each sample pertains
to from a single file. The PPI data can be simply a two-
column comma-separated file with each row containing the
names of interacting genes.
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Integrated optimization algorithm
IODNE achieves detection of the subnetworks based on two
groups’ transcriptome comparison and existing PPIs, such as
the tumors and the adjacent tumor normal groups. Figure 1
shows the IODNE algorithm workflow. It consists of four
modules: (1) gene expression-based scoring; (2) protein
interaction-based scoring; (3) two networks node and edge
scores integration; and (4) identification of the maximal scor-
ing subnetwork algorithm. The genes are first scored based
on the gene-expression data. For this, the concept of Pearson
correlation is applied. Second, the protein interaction network
scoring is based on the influence of the genes and gene pairs
on the PPI network at large. This strategy is a partial adapta-
tion of the Vandin et al.34 HotNet algorithm. Third, edge scores
and the node scores from the gene control network and the
PPIs network score sets are scaled by an associated scale
value for each network and combined by summation. The
scoring functions that evaluate the edge scores of gene pairs
and the node scores of individual genes are given below.
Fourth, the scored network is subjected to the search strategy
for the maximal edge-scoring subnetwork, with a size below a
user-defined threshold number of genes. The search strategy
uses a customized version of the modified minimum spanning
tree Kruskal algorithm.35,36 Each of the steps are described
below, after descriptions of the data required for the analysis
and the preprocessing.
Step 1. Gene-expression based scoring strategy on
nodes and edges in construction gene regulatory
network
Node score. To compare two groups’ transcriptomes, such
as tumor and normal groups, a two group t-test with equal
variance for unequal sample sizes is performed to find dif-
ferentially expressed genes (DEGs) as follows:
t5
Xn2 Xt
SXt Xn :
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nt
1 1nn
q
where SXtXn 5
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nt21ð ÞSXt 22 nn21ð ÞSXn 2
nt1nn22
r
; Xt 5mean of the tumor
samples; Xn 5mean of the normal samples; nt 5 number of
tumor samples; nn5 number of normal samples; SXt 5
standard deviation of the tumor samples; and SXn5 stan-
dard deviation of the normal samples. Given the degrees of
freedom: df5nt1nn22, checking the P value p associated
with a t-value t for two-tailed t-test in the t-distribution. The
sign of t means the gene is down (t >0) or up (t <0)
regulation in tumors comparing with normal group. Here,
we set gene (node) score as abstract t-value t in gene-
gene interaction network: NS15 |t|.
Edge score. The scoring pipeline of IODNE starts with the
scoring of the gene-expression profiles. For every pair of
gene x and gene y, we calculate Pearson correlation coeffi-
cients between x and y as follows:
r5
X x2 xð Þ y2yð ÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
x2 xð Þ2P y2yð Þ2q
where x ; y 5 individual values of the gene in the cohort
(tumor or normal group); x , y 5 average of the gene
across the samples in tumor or normal group. Thus, Pear-
son correlation coefficient of the gene pair (x, y) is calculat-
ed in the tumor group as rt x ; yð Þ and the normal group as
rn x ; yð Þ, respectively. The differential correlation of gene
pair (x, y) shows the control distance difference between
the tumor group and the normal group denote as:
Dr5 jrn2rt j:
This represents the edge score of each gene pair (x, y) in
the gene-gene interaction network: ES15Dr .
Step 2. Protein-protein interaction based scoring
strategy in nodes and edges
A Laplacian matrix is used to discover the relationship
between network topological structure and its gene connec-
tion features in the PPI network, as in the literature.35 Giv-
en a simple PPI graph, G with n genes (nodes), the
symmetric normalized Laplacian matrix is defined as:
L5D2A
where A5 aij
 
n3n
is the binary adjacency matrix of PPI
graph G, aij is equal to 1 or a value ranging from 0 to 1. If
gene i and j are linked in the network aij51, otherwise
aij50; D5 dij
 
n3n
is the degree matrix of graph G, where
dii5
Pn
j51 aij , and dij50, for i 6¼ j.
A Hotness matrix is defined to reflect the influences of
one gene against other genes34 as follows:
H5e2Lc
where H5 hij
 
n3n
represents the connection influence
between gene i and gene j, c is a constant, and default
value is c 5 0.1.
Node score. Node score rx is to evaluate the gene x
influence to the whole PPIs network. It is calculated as the
sum of all the influences of the genes with its connections,
which is the sum of row margins to Matrix AH. For
instance, if a gene x has two connected genes y and z, the
node score of gene x would be:
rx5 h x; yð Þ1h x ; zð Þ:
Edge score. The edge score for each of the gene pairs
(x, y) is calculated from the max node score of the individu-
al genes of the pair multiplied with the binary adjacency
score of the gene pair as follows:
Table 1 Samples input formats for two groups’ comparison
Groups
Adjacent
normal
Adjacent
normal Tumor Tumor
Subtypes Basal-like Luminal A Basal-like Luminal A
Samples
genes
TCGA-A7-
A0CE-11A-
21R-A089-07
TCGA-A7-
A0CH-11A-
32R-A089-07
TCGA-A7-
A0CE-01A-
11R-A00Z-07
TCGA-A7-
A0CH-01A-
21R-A00Z-07
FKBPL 20.92533 20.639 20.23283 0.324167
COL10A1 0.71875 2.121 4.655 6.3255
KIF26B 1.4585 0.28925 1.27575 2.76125
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w x ; yð Þ5maxfrx; ryg  axy :
Denoted the node score and edge scores as NS25 r,
ES25w .
Step 3. Node score and edge score integration of gene
regulatory network and protein-protein integration
network
In order to maintain the equal influences from the two net-
works in integration, scaling node score and edge score
need be done by the ratio of maximum scores from either
scoring to each of the genes in the two networks as
follows:
Node weights : NSnet5NS11 / NS2
Edge weights : ESnet5 ES11b  ES2
where /5 {max NS1/max NS2}, b5 {max ES1/max (ES2)}.
In the merged network, node weights (gene) carry two
messages, one is the gene expression difference of tumors
verse normal group, and another one is the gene influence
Figure 1 The overview of integrated optimization method for identifying the dysregulated subnetwork showing the scoring and search workflow.
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ability (connection degree) in PPIs. Meanwhile, edge weight
for a pair of genes carries the similar two messages: the
pair-gene connection difference of tumors vs. its normal
group in the gene regulatory network, and the gene con-
nection strength in PPIs.
Step 4. Search strategy
The IODNE algorithm uses both informative node weights
and edge weights derived from prior knowledge. It sorts all
the edge weights in a descending manner, and then
extracts subnetworks with k-connected genes in sequence
based on the modified Kruskal searching algorithm by
drug-target gene weight ranking. Given an undirected graph
G5 (V, E, w(v),w(e)), where V is a set of nodes with weight
w(v), E is a set of edges with weight w(e). IODNE algorithm
is an integer linear programming-based optimum algorithm
described as follows. The minimum spanning tree by the
node and edge weight is used to search the subgraph to a
limited number size k:
min C=
Xk1
i51
w við Þ1
Xk2
j51
w ej
  !
s:t: k1  k
C is constant.
IODNE is used to extract a subset of the edges in a giv-
en undirected graph with three properties: (1) it includes k
vertices in the subgraph; (2) the total weight of all the
edges is as largest as possible; and (3) there is no cycle in
the subgraph. At the same time, two enforcing functions
that counteract and refine the subnetworks are added:
(1) orphan node pairs that are not connected to the parent
subnetwork are removed; (2) for the nodes with an abnor-
mally high number of leaves (greater than a declared
threshold – defaulted to 30), the five edges with the largest
weights are kept and the remaining are pruned out of the
subnetwork. A more elaborate explanation is as follows:
Additionally, it is sometimes necessary to filter out nonsig-
nificant genes before we use our algorithm on large datasets.
A typical experiment is to select the DEGs by comparing the
transcriptome profiles between an experimental group and its
control group. The dysregulated genes are then selected
using one of multiple possible criteria. For example, the dys-
regulated genes can be defined as those genes that surpass
a fold change threshold and P value threshold after a two-
group t-test. These genes will then be investigated for con-
nected subgraphs using the IODNE algorithm.
Step 5. Software developing and code
IODNE code is written in Java and compiled with Java Devel-
opment Kit version 1.7. Its installation and run notes are
available in the Supplementary Code File. The original pro-
gram is accessible to: https://drive.google.com/open?id50B9-
cfjp2iWgONjU4a3hwQ2RKcW8.
RESULTS
Here, we show that IODNE selects subnetworks, which
contain ER1/PR and HER2, the well-known targets in clini-
cal Luminal-A breast cancer subtypes, validating our
results. In addition, IODNE is applied to TNBC, providing
potentially novel gene targets for drug selection.
Subnetwork identification for Luminal-A subtype of
breast cancer
DEGs to 43 pairs of TCGA tumor and corresponding
adjacent-normal samples are calculated by unpaired two-
group t-test in the tumor vs. the normal group first (Supple-
mentary File S2). IODNE begins with the application of
t-value or P value thresholds filters to the gene list that is
input into the algorithm by user desired. In the analysis,
nondysregulated genes were filtered by P value P< 0.15 to
reduce the noise in the output as well as substantially
increase the runtime performance of the algorithm. A rela-
tively high P value threshold is selected here in order to
keep many of the transcription factors and enzymes in
IODNE, such as well-known genes ESR1 and PGR. These
genes exert important control over the gene network,
despite that they do not show statistically significant expres-
sion variation between tumor vs. normal samples.
Our aim here was to use the DEG characteristics to iden-
tify possible targets for drug development in integrated
gene and protein network. Genes that are expressed more
strongly in tumors than the adjacent normal tissue (t-value
t <0 upregulation gene in tumors, P< 0.05) can potentially
serve as drug targets. Supplementary Files S4 and 5 pro-
vide the gene list of potential cancer drugs and FDA
approved drugs, respectively. However, we need discover
which targets are the optimum ones and the hub genes
(the nodes with high degree in the network), which are
yielded with the correspondingly high edge weights in the
integrated gene and protein networks.
The highest edge weight subnetwork in Luminal-A breast
cancer was obtained using the IODNE algorithm with size
k5 36 and the FDA approved drug target list used for rank-
ing nodes’ weights. The analysis retrieved the subnetwork
containing 36 genes connected with 58 edges. Cytoscape
Algorithm: Modified Kruskal minimum spanning tree algorithm.
Input: (1) A weighted, undirected graph G5 (V, E, w(v), w(e))
and (2) the maximum allowed nodes per graph k.
Output: A maximally edge-weighted tree T.
Procedure: Sort the nodes (drug target genes) in V in decreas-
ing order by node-based score (weight).
Select the largest score node vlargest in V.
T  Select the largest edge (u, v) for node vlargest
in its edge list.
Sort the edges in E in decreasing order by edge-
based score (weight) around nodes u, v.
For each edge (u1, v1), in sorted order:
Determine the closest neighbor of the selected
edge.
x  Find u1ð Þ:
y  Find v1ð Þ:
If x 6¼ y then:
T  T [ u1; v1ð Þf g
Union (x, y)
Until the total node size in the network is k.
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3.437 was used to visualize these selected genes’ interac-
tion networks and denote the drug targeted genes from
DrugBank annotations (Figure 2). Here, the nodes are col-
ored according to degree to make obvious the hubs of the
subnetwork. The subnetwork contains two very prominent
biomarkers – PGR and ERBB,38 as well as some new
genes never reported as drug targets before, including
HRAS, POLE, AFG3L2, and SLC2A1.
Subnetwork identification for the triple-negative breast
cancer subtype of the breast cancer application
We analyzed the gene expression profiles of nine pairs of
cancer and adjacent normal samples of patients with TNBC
from TCGA. A listing of DEGs by unpaired two-group t-test
for the tumors vs. the normal samples is provided in Sup-
plementary File S3. IODNE was used to select the dysre-
gulated optimum subnetwork for the TNBC subtype of
breast cancer with the FDA approved drug target list used
for ranking nodes’ weights in the integrated gene and protein
networks. The genes were filtered by P values (< 0.05) and
the t-value (<0) for significant DEGs between the case and
adjacent-normal groups. These significant DEGs were input
into the IODNE algorithm, with a k value of 59. Supplemen-
tary Files S6 and S7 list the target genes of potential can-
cer drugs and FDA approved drugs, respectively, for TNBC.
Figure 3 shows the subnetwork for the TNBC subtype of
breast cancer consisting of 59 genes and 112 edges by
Cytoscape 3.4 visualization. The network contains 12 drug
targets by DrugBank annotation39 that are highlighted in
green in the subnetwork. The most connected hub is glycer-
aldehyde 3-phosphate dehydrogenase, which has been
shown to play a crucial role in cancer regulation,40 although
it does not show significant differential expression between
TNBC tumor samples vs. their adjacent-normal samples.
The other targets include HSP90B1, ME2, TUBB3, APRT,
AXIN1, CAD, RDH13, POLE, DAPK1, HDAC6, and
SLC2A1.
DISCUSSION
Subnetwork analysis can explore complex patterns in the
entire network of molecular pathways for the purpose of
cancer genes and drug target identification. IODNE is a
robust and powerful algorithm for the identification of sub-
networks for cancer genes and drug targets. The applica-
tion of the IODNE for subnetwork selection of drug target in
breast cancer subtypes Luminal-A show well-known targets
PGR and ERBB2 in clinical are found. In addition, our
results show IODNE can find genes in the subnetwork,
which play a significant role in breast cancer. The HRAS
gene is directly related to the tumor aggressiveness in
Figure 2 Subnetwork of subtype Luminal-A breast cancer.
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breast cancer41 and the POLE gene has been linked to the
increased risk of colorectal cancer.42 The most connected
hub genes in the subnetwork are DHX15 and CCT2. CCT2
is found to be necessary for growth/survival of breast can-
cer cells in vitro.43 All of these results would seem to vali-
date the utility of the IODNE algorithm. TNBC treatment is
centered on chemotherapy. The discoveries in the molecu-
lar profiling of TNBC press the need to explore new targets
in TNBC at the intersection of precision medicine and
molecular profiling. IODNE is applied to TNBC data for the
drug-target subnetwork identification. The genes ERBB2,
HRAS, PGR, CAD, POLE, and SLC2A1 are identified as
significant in TNBC, which strong research evidence28 iden-
tifies as drug-target candidates.
IODNE has many advantages, some of which include:
(i) the scoring strategy takes into account both gene
expression and PPI profiling. This gives a multidimensional
assessment in finding the most significant subnetwork.
Figure 3 Subnetwork for triple-negative breast cancer subtype of breast cancer.
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(ii) The node scores and edge scores are rationally com-
bined through scaling parameters. This scaling is crucial in
balancing both the gene expression and PPI metrics with-
out a bias. (iii) The search algorithm is tailored to consider
every edge in the network while deriving the most signifi-
cant network with the largest connection. The final subnet-
works are free from orphan edges increasing the
comprehensiveness of the output. Unfortunately, the
IODNE approach has limitations too. We did not define a
re-sampling subnetwork mechanism to remove potential
false-positive issues under these huge sets of gene interac-
tions. In addition, IODNE cannot extend network-based
drug target selection to precision medicine on an individual
patient basis. Two potential avenues for extending the cur-
rent algorithm include: (1) incorporating mutational and
copy number variation profiling data along with gene
expression profile and drug targets under a systems biology
framework may lead to significant improvements in preci-
sion oncology.44 Driver gene mutations tend to have a
selective growth advantage in tumor cells and play a dis-
proportionate role in cancer biology. The possibility of tar-
geting driver mutations in a gene control network, which
can be further studied in the emerging field of precision
cancer medicine.44–46 (2) Extending the IODNE algorithm
to an individualized systems medicine approach to optimize
precision cancer therapies to be more safe and effective for
individual patients is another important direction for preci-
sion cancer medicine.47 That would enable IODNE to
extend its function to a single-patient level as well.
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